StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, OncoCyte presently has a consensus rating of “Hold” and a consensus price target of $4.06.

OncoCyte Price Performance

Shares of NASDAQ OCX opened at $3.14 on Wednesday. The business has a fifty day moving average of $3.08 and a two-hundred day moving average of $2.92. OncoCyte has a 52-week low of $2.08 and a 52-week high of $4.34.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.